Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Izotropic ( (TSE:IZO) ) is now available.
Izotropic announced the filing of a pre-submission with the U.S. FDA for the approval of its IzoView Breast CT Imaging System, designed for breast cancer screening in women with dense breast tissue. This advancement responds to a significant need for high-resolution imaging modalities that can improve early detection rates, potentially expanding the market size for IzoView scans by 800%, thus enhancing Izotropic’s market positioning and addressing critical healthcare demands.
More about Izotropic
Izotropic Corporation is a medical device company focused on developing imaging-based products using innovative and emerging technologies for the accurate screening, diagnosis, and treatment of breast cancers.
YTD Price Performance: 150.0%
Average Trading Volume: 76,117
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.52M
Find detailed analytics on IZO stock on TipRanks’ Stock Analysis page.